Key result
Long-term nifedipine monotherapy significantly reduced left ventricular mass by a mean of 15% in patients with systemic hypertension.
Why the study?
Does nifedipine monotherapy reduce left ventricular hypertrophy in patients with systemic hypertension?
Observational (n=9)
Does nifedipine monotherapy reduce left ventricular hypertrophy in patients with systemic hypertension?
Long-term nifedipine monotherapy significantly reduces blood pressure and reverses left ventricular hypertrophy in patients with systemic hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for nifedipine in hypertensive LVH; leaves open confirmation in randomized trials.
We investigated the regression of left ventricular (LV) hypertrophy with long-term treatment of nifedipine in patients with systemic hypertension. Echocardiograms of the LV were obtained in nine patients before and at a mean of 50 months (13-105 months) after nifedipine monotherapy (30-60 mg/day). Nifedipine significantly reduced both systolic and diastolic blood pressures (BP) by a mean of -46 mmHg and -21 mmHg, respectively. With systemic BP reduction, LV mass was significantly reduced by a mean of -15%, associated with a decrease in LV posterior wall thickness and end-diastolic dimension. There was no significant change in LV fractional shortening. We conclude that nifedipine may cause regression of LV hypertrophy in systemic hypertension, and that reversal of the increase in LV mass could be maintained during long-term nifedipine treatment.
No takes yet. Share an insight, caveat, or question.
Yamakado et al. (1994) conducted an observational in Systemic hypertension (n=9). Nifedipine vs. Baseline was evaluated on Left ventricular mass. Long-term nifedipine monotherapy significantly reduced left ventricular mass by a mean of 15% in patients with systemic hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: